

THE LANCET

Microbe

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Au WY, Cheung PPH. Diagnostic performances of common nucleic acid tests for SARS-CoV-2 in hospitals and clinics: a systematic review and meta-analysis.
Lancet Microbe 2021; published online Oct 12. [https://doi.org/10.1016/S2666-5247\(21\)00214-7](https://doi.org/10.1016/S2666-5247(21)00214-7)

Supplementary appendix

Diagnostic Performances of Common Nucleic Acid Tests for COVID-19 in Hospitals and Clinics: A Systematic Review and Meta-analysis

Wing Ying Au^{a,b,c}, BSc, Pak Hang Peter Cheung^{a,b,c}, PhD

^aLi Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China

^bDepartment of Chemical Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China

^cDepartment of Chemistry, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR

*To whom correspondence may be addressed. Email: ppcheung@cuhk.edu.hk, Room 306F, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China, Tel: (852) 37636049

Supplementary Table 1. Summary of content of 66 studies

Supplementary Table 2. Primary subgroup analysis for LAMP, dPCR, and qPCR assays using bivariate latent class model

Supplementary Table 3. dAUC and P values of LAMP, dPCR, and qPCR

Supplementary Table 4. Sensitivity, specificity, and DOR in secondary subgroup analysis by clustering

Supplementary Table 5. Summary of primer-probe sets for 66 studies

Supplementary Table 6. Summary of index tests and reference tests of all included studies

Supplementary Figure 1a-c. Forest plots of LAMP, dPCR, and qPCR

Supplementary Figure 2. Galaxy plots of LAMP, dPCR, and qPCR studies to visualize heterogeneity

Supplementary Figure 3. Graph of methodological quality for the 66 studies

Supplementary Table 1. Summary of content of 66 studies

Total number of included studies = 66, total number of samples = 15,017 (both number of patients and samples generated from the same population).

Abbreviations: Chest CT, Chest computed tomography; CDC, Centers for Disease Control and Prevention; dPCR, digital polymerase chain reaction; LAMP, loop-mediated isothermal amplification; ORF, open reading frame; RdRP, RNA-dependent RNA polymerase; qPCR, quantitative polymerase chain reaction

| Study (N=66) | Sam- ple size | Test type | Target gene | Specimen type | Patient type/ Subject | Control | Measurement of concentration of genetic sequences in mixture | Extraction of RNA | Choice of toolkit |
|----------------------|---------------------|---------------------------|---------------------|--------------------------------|---|---|--|--|---|
| Abasi-yanik, 2020 | 166 | dPCR qPCR | N1 N2 | Nasal swabs Saliva | Inpatients(hospitalized), outpatients, asymptomatic individuals | Internal control RnaseP gene | Fluorescence read by QX200 reader - BioRad for dPCR; Ct values evaluated by CFX MaestroTM Software (Bio-Rad) for qPCR | RNA extraction by QIAamp MinElute Virus DNA/RNA Spin Kit (QVDRK) (Qiagen) and QIAamp Viral RNA Mini Kit (QVK) (Qiagen) | CFX384 Touch Real-time PCR detection system (Bio-Rad) for qPCR |
| Alteri, 2020 | 55 | dPCR qPCR IgG assay | RdRp | Nasopharyngeal swabs | Patients confirmed with COVID-19 | Negative control with 40 samples; Positive control with 60 samples | Fluorescence read in FAM and HEX channels for dPCR | RNA extraction by QIAamp viral RNA mini kit | GeneFinder™ COVID-19 Plus RealAmp Kit for qPCR; QX200™ BioRad for dPCR |
| Cassinari, 2020 | 130 | dPCR qPCR | ORF1ab RdRp N | Nasopharyngeal swabs Saliva | Ambulatory patients with mild to moderate infection | Unspecified | Fluorescence read by QX200 reader - BioRad for dPCR | RNA extraction by EZ1 DSP 96 virus kit (Qiagen, Hilden, Germany) and EZ1 Advanced XL machine | RealStar® 97 SARS-CoV-2 RT-PCR Kit 1.0 for qPCR |
| Dang, 2020 | 117 | dPCR qPCR | ORF1ab N | Pharyngeal swabs Sputum | Patients confirmed with and without COVID-19 | Positive control using a reference gene | Fluorescence read in FAM/VIC channels or Evagreen by chip reader, TargetingOne, Beijing for dPCR | RNA extraction by Nucleic acids extraction kit Lot. T124 | TD-1™ Droplet Digital™ PCR System; SARS-CoV-2 detection kit, Biogerm Medical Biotechnology for qPCR |

| | | | | | | | | | |
|---------------------------|-----|-------------------------------|------------------|---------------------------------|--|--|--|--|--|
| Deiana, 2020 | 50 | Regular dPCR One-step dPCR | N1 N2 | Nasopharyngeal swabs | Universal Transport Medium ESwab Both collected from COVID-19 patients | Positive control No template control | Fluorescence read in FAM and HEX channels by QX200 reader -BioRad for dPCR | RNA extraction by Nextractor NX-48 using the NX-48S Viral NA Kit (Genolution Inc.) | 2019-nCoV CDC dPCR triplex probe assay (dEXS28563542, Bio-Rad) for dPCR |
| Dong, 2020 | 146 | dPCR qPCR | ORF1ab N E | Pharyngeal swabs | Hospitalized Patients, close contacts and convalescents | Positive human reference control using RNAsep in VIC channel | Fluorescence read in FAM and VIC channels by QX200 reader -BioRad for dPCR | RNA extraction by MagMAX-96 viral RNA isolation kit | QX200™ BioRad for dPCR; kits from H&R, Biogerm Medical Biotechnology, Daan for qPCR |
| Liu, 2020 | 92 | dPCR qPCR | N | Feces Sputum Throat swabs | Recovering COVID-19 patients Relapsed patients (secondary infection) | Synthetic DNA fragment from the N gene as a positive control; ultrapure water as a negative template control; internal control | Fluorescence read in the VIC, ROX and CY5 channels by Droplet Digital PCR System (Pilot Gene Technologies (Hangzhou) Co., Ltd) | RNA extraction by Nucleic Acid Extraction Kit (Shanghai ZJ Bio-Tech Co., Ltd) | Novel Coronavirus Real Time qPCR Kit (Shanghai ZJ Bio-Tech Co., Ltd) for qPCR |
| Oberding, 2020 | 12 | dPCR qPCR | E | Saliva | Patients with post symptom-onset | Positive control using 5 templates for dPCR No template controls | Fluorescence read by (QX200™ Droplet Digital™ (dd) PCR system | RNA extraction by Promega SV total RNA 64 (Promega Corp., Madison, WI) | Unspecified toolkit for qPCR |
| Suo, 2020 | 63 | dPCR qPCR | ORF1ab N | Throat swabs | Outpatients and convalescents | Positive control for both dPCR and qPCR using same primer/probe set | Fluorescence read in FAM and HEX channels by QX200 reader -BioRad for dPCR | RNA extraction by QIAamp viral RNA mini kit | QX200™ Droplet Digital PCR System for dPCR; BioRad CFX96 Touch Real-Time PCR Detection system for qPCR |

| | | | | | | | | | |
|--------------------|-----|--------------|------------------|--|---|--|---|--|--|
| Y. Jiang, 2020 | 32 | dPCR qPCR | ORF1ab N | Pharyngeal swabs Throat swabs Phlegm Plasma Eye conjunctiva | Confirmed COVID-19 patients | Unspecified | Fluorescence emit- ted by TaqMan probes | RNA extraction by RNA release agent (Shengxiang, Hunan, China) | Droplet Digital PCR Sys- tem (Changchun Technical Biotechnology Co., Ltd. Changchun, China) and the SARS-CoV-2 Nucleic Acid Detection Kit (Shanghai Rightongene Biotechnology Co., Ltd. Shanghai, China) for dPCR |
| Yu, 2020 | 323 | dPCR qPCR | ORF1ab N | Nasopharyngeal swabs Throat swabs Sputum Urine Plasma | Confirmed and suspected patients; patients showing respiratory symp- toms but did not meet criteria for suspected cases; convalescents | Positive control us- ing a reference gene | Fluorescence read in FAM/VIC chan- nels or Evagreen by chip reader, Target- ingOne, Beijing for dPCR | RNA extraction by QI- Aamp viral RNA mini kit | COVID-19 digital PCR detection kit (Target- ingOne, Beijing, China) and TargetingOne Digital PCR System (CFDA) for dPCR; reaction system from BioGerm Medical Technology for qPCR |
| Altawalah, 2020 | 891 | qPCR | ORF1ab N S | Nasopharyngeal swabs Saliva | Suspected COVID-19 pa- tients | Negative and posi- tive controls | Fluorescence emit- ted by TaqMan probes | RNA extraction by MagMax Viral/Patho- gen Nucleic Acid Iso- lation Kit (Thermo Fisher Scientific, Wal- tham, MA, USA) | TaqPath™ COVID-19 multiplex real-time RT- PCR test (Thermo Fisher Scientific, Waltham, MA, USA) for both index and reference qPCR tests |
| Anderson, 2020 | 494 | qPCR | N | Nasopharyngeal swabs | Unspecified | Human specimen control using Rnase-P (RP) gene | Fluorescence emit- ted by TaqMan probes | RNA extraction by MagNA Pure 24 Total NA Isolation kit (Roche) | CDC RT-PCR COVID-19 assay using TaqPath 1- Step RT68 qPCR Master Mix, CG kit (Life Tech- nologies) for both index and reference qPCR tests |

| | | | | | | | | | |
|--------------------------|-----|-------------|----------------|--|---|--|--|---|--|
| Barra, 2020 | 63 | qPCR | E N RdRP | Nasopharyn- geal/ oropha- ryngeal swabs | Unspecified | Human specimen control using RNase-P (RP) gene | Fluorescence emit- ted by TaqMan probes | RNA extraction by MagNA Pure 96 In- strument and MagNA Pure 96 DNA and Viral NA Small Volume Kit (protocol Viral NA Universal version 4.0) | LightCycler 480 II on Flow Flex system |
| Bruce, 2020 | 155 | Direct qPCR | N1 N2 N3 | Nasopharyngeal swabs | Unspecified | Internal control pri- mer/probe set for detection of human RNase P | Fluorescence emit- ted by TaqMan probes | RNA extraction by QI- Aamp Viral RNA Mini Kit (Qiagen, Cat. No. 52904) and Roche MagNA Pure 96 platform (Roche Lifesciences) for reference test only | NEB Luna Universal Probe One-Step RT-qPCR Kit Thermo Fisher TaqPath 1- Step RT-qPCR Master Mix, CG AgPath-ID One-Step RT- PCR kit |
| Chan, 2020 | 273 | qPCR | RdRp N S | Pharyngeal swabs Saliva Sputum Plasma Urine Rectal swabs | Confirmed COVID patients | Positive controls | Fluorescence emit- ted by sequence- specific probes | RNA extraction by NucliSENS easyMAG extraction system (bio- Mérieux, Marcy-l'Étoile, France) | QuantiNova Probe RT- PCR kit (Qiagen) in a LightCycler 480 real-time PCR system (Roche, Ba- sel, Switzerland) for both index and reference qPCR tests |
| Dorlass, 2020 | 63 | qPCR | E | Pharyngeal swabs | Symptomatic pa- tients and Asymptomatic healthcare workers | Positive controls using clinical isolated in Vero-E6 cell cul- ture Negative control using water | SYBR Green for in- dex PCR test TaqMan for refer- ence PCR test | RNA extraction by NucliSens easyMag® platform (BioMerieux, Lyon, France) | QuantiFast SYBR® Green RT-PCR kit (QIAGEN, Hilden, Germany) for index qPCR test one-step protocol used the Pyromark OneStep RT-PCR kit (QI- AGEN, Hilden, Germany) for reference qPCR test |

| | | | | | | | | | |
|-------------------------|-----|-------------|-------------------|-----------------------------------|---------------------------------------|--|--|---|---|
| Freire, 2020 | 54 | qPCR | N1 N2 | Nasopharyngeal swabs | Suspected COVID-19 patients | Positive controls using 2019-nCoV N (IDT, USA) | Unspecified probe type | RNA extraction by CFX96 BioRad instrument and PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) | nCoV-QS (MiCo BioMed) kit for index qPCR test 2019-nCoV CDC EUA kits for reference qPCR test |
| Garcia, 2020 | 172 | qPCR | N1 N2 | Nasopharyngeal swabs | Unspecified | Positive control using commercial 2019-nCoV N Negative controls (TE pH 8 buffer) | Fluorescence emitted by TaqMan probes | RNA extraction by AccuPrep Viral RNA extraction kit (Bioneer, South Korea) | TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, USA) and CFX96 thermal cycler (BioRad) for both index and reference qPCR tests |
| Hasan, 2020 | 132 | Direct qPCR | E | Nasopharyngeal swabs | Unspecified | Internal control using MS2 bacteriophage template | RNA concentration measured by using Qubit® RNA HS (High Sensitivity) Assay Kits (Thermo Scientific™) on an Invitrogen Qubit® 4 Fluorometer (Thermo Scientific™). | RNA extraction by NucliSENS1 easyMAG platform (bioMe’rieux, France) | SARS-CoV-2 RT-qPCR with TaqPath™ 1-Step RT-qPCR kit for both index and reference qPCR tests |
| Jung, 2020 | 15 | qPCR | N ORF1 RdRP | Upper respiratory tract specimens | COVID-19 patients Healthy subjects | Unspecified | RNA concentration measured by Quantus Fluorometer (Promega, Madison, WI, USA) | RNA extraction by QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany) | CFX 96 touch real-time PCR detection system (Bio-Rad, Hercules, CA, USA) |

| | | | | | | | | | |
|-------------------------|-----|--------------|--------|---|-------------------------------------|--|---|--|---|
| Kandel, 2020 | 432 | qPCR | E | Nasopharyngeal swabs Saliva | Outpatients | Armored RNA in- ternal control | Fluorescence emit- ted by TaqMan probes | RNA extraction by BD MAXTM system using the ExK TNA-2 strip (Becton, Dickinson, ND, USA) | CFX96 Touch Real-time PCR detection system (Bi- oRad, Canada) for naso- pharyngeal swabs Roche cobas® SARS- CoV-2 assay (Ho- mann-La Roche Limited, Mississauga, ON, Canada) for saliva |
| Klein, 2020 | 77 | qPCR LAMP | E N | Upper respira- tory tract speci- mens | Positive and nega- tive patients | Internal control | Unspecified | RNA extraction by SiMAG-N-DNA mag- netic beads (Chemi- cell, Berlin, Germany) in 96 deep-well plate format for index test QIAamp Viral RNA body fluid kit for refer- ence test | LightCycler® Multiplex RNA VirusMaster kit, Berlin, Germany for qPCR WarmStart® Colorimetric LAMP 2X Master Mix M1800 (New England Biolabs, Ipswich, MA, USA) for LAMP |
| Konrad, 2020 | 73 | qPCR | E | Nasopharyngeal swabs or sputum | Patients and con- tact persons | Positive controls using Wuhan coro- navirus 2019 E gene and SARS- CoV Frankfurt 1 genomic RNA, negative extraction and no-template controls LightMix Modular Wuhan CoV RdRP- gene (TibMolbiol, Berlin, Germany) for SARS-CoV-2 assay | Fluorescence emit- ted by sequence- specific probes | Unspecified RNA ex- traction kit | RealStar SARS-CoV-2 RT-PCR kit 1.0 (Altona, Hamburg, Germany) for both index and reference qPCR tests |

| | | | | | | | | | |
|---------------------------|-----|-------------|---------------------|--|----------------------------|--|--|--|--|
| Lübke, 2020 | 91 | Direct qPCR | E | Pharyngeal swabs Tracheal secretion Bronchoalveolar lavage fluid Aspirate Saliva | Unspecified | Internal control using synthetical plasmid coding for s-Antigen of Hepatitis B | Fluorescence emitted by TaqMan probes | Not required for direct PCR RNA extraction by MagNA Pure 96 system (Roche, Penzberg, Germany) for in-hoFuse PCR | In-house qPCR with the protocol by Corman and colleagues OR cobas® SARS-CoV-2 test (Roche) for both index and reference qPCR tests |
| McCor-mick-Baw, 2020 | 156 | qPCR | N2 E | Nasopharyngeal swabs Saliva | Positive COVID-19 patients | Internal controls | Fluorescence signal from the probes | Unspecified RNA extraction kit | Cepheid Xpert Xpress SARS-CoV-2 (Sunnyvale, CA) for index qPCR test |
| Merindol, 2020 | 88 | qPCR | N E S RdRp | Pharyngeal swabs | Unspecified | Internal controls | Fluorescence emitted by sequence-specific probes | RNA extraction by following the standard Altona method and the SeeGene protocol | RealStar® 76 SARS-CoV-2 RT-PCR Kit RUO for index qPCR test SeeGene AllplexTM 78 2019-nCoV RT-QPCR Assay for reference qPCR test |
| Moreno-Contreras, 2020 | 253 | qPCR | E | Pharyngeal swabs Saliva | Ambulatory patients | Internal controls using human RNase P gene | Fluorescence emitted by sequence-specific probes | RNA extraction by QIAamp viral RNA mini kit | StarQ One-Step RT-qPCR (Genes 2 Life) kit for both index and reference qPCR tests |

| | | | | | | | | | |
|----------------------------|------|------|------------------------|----------------------|-------------|---|---------------------------------------|--|---|
| Perchetti, 2020 | 356 | qPCR | N1 N2 | Nasopharyngeal swabs | Unspecified | Internal controls using EXO (a 130-base RNA transcript derived from jelly-fish DNA) | Fluorescence emitted by TaqMan probes | RNA extraction by Roche's MagNA Pure 96 instrument | AgPath-ID One-Step RT-PCR Kit (Life Technologies, Carlsbad, CA) for both index and reference qPCR tests |
| Pujadas, 2020 | 1006 | qPCR | ORF1a E N1 N2 | Nasopharyngeal swabs | Unspecified | Internal controls using human RNase P gene | Unspecified probe type | RNA extraction by QIAamp Viral RNA Mini Kit (Qiagen) for laboratory developed test or EZ1 DSP Virus Kit (Qiagen) | QuantiFast Pathogen RT-PCR Kit (Qiagen) in a LightCycler 480 II (Roche) for both index and reference qPCR tests |
| Ranoa, 2020 | 100 | qPCR | N1 N2 | Saliva | Unspecified | Internal controls using MS2 bacteriophage | Fluorescence emitted by TaqMan probes | RNA extraction kit for reference test unspecified | TaqPath/MasterMix qPCR for reference qPCR test |
| Ratcliff, 2020 | 43 | qPCR | N RdRp | Nasopharyngeal swabs | Unspecified | Synthetic controls including SARS-CoV-2 RNA Control 1 - MT007544.1 and Control 2 - MN908947.3 | Unspecified probe type | RNA extraction by Qi-asymphony DSP virus/pathogen minikit | Applied Biosystems StepOnePlus Real-Time PCR System (ThermoFisher Scientific) for both index and reference qPCR tests |

| | | | | | | | | | |
|----------------|-----|-------------|------------------|--------------------------------|--|--|--|---|---|
| Sun, 2020 | 564 | qPCR | ORF1ab N E | Nasopharyngeal swabs Saliva | positive COVID patients | Internal controls using human RNase P gene | Fluorescence emitted by sequence-specific probes | RNA extraction by MGISP-960 or Thermo PureLink™ Viral RNA/DNA Mini Kit | QuantiVirus™ SARS-CoV-2 Multiplex Test for index qPCR test ABIQ5 qPCR instrument for reference qPCR test |
| Vaz, 2020 | 155 | qPCR | E RdRp | Pharyngeal swabs Saliva | Symptomatic healthcare workers and inpatients | Protocol presented in foreign language | Protocol presented in foreign language | RNA extraction by QIAGEN QIAamp®RNA Mini Kit | BIOMOL OneStep/ COVID-19 Kit (Paraná Molecular Biology Institute) protocol for both index and reference qPCR tests |
| Visseaux, 2020 | 83 | Direct qPCR | E S RdRP | Nasopharyngeal swabs | Hospitalized patients | Unspecified | RNA quantified by standardized RNA transcript control obtained from the European Virus Archive Program | RNA extraction by MagNA Pure LC Total Nucleic Acid Isolation Kit - Large Volume (Roche Diagnostics) | ABI 7500 plateform (Applied Biosystems®) |
| Vogels, 2020 | 67 | qPCR | N1 N2 | Nasopharyngeal swabs Saliva | COVID-19 diagnosed patients and healthcare workers | Internal controls using human RNase P gene | Fluorescence emitted by modified fluorophore (Cy5 instead of FAM) | Not required for direct PCR RNA extraction by MagMax Viral/Pathogen Nucleic Acid Isolation Kit (paired with TaqPath) | SalivaDirect protocol for index qPCR test ThermoFisher Scientific TaqPath COVID-19 combo kit for reference qPCR tests |

| | | | | | | | | | |
|------------------|-------|------|----------------|--|---|---|---------------------------------------|--|---|
| Wang, 2020 | 181 | qPCR | ORF1ab N | Throat swabs | Suspected COVID patients | Positive control using recombinant plasmids Negative control using nonribozyme water | Fluorescence emitted by TaqMan probes | RNA extraction by Tian Long automatic extraction kit (Tian Long, Xi'an, China) | qRT-PCR kit (Sansure, Hunan, China) for both index and reference qPCR tests |
| Wolters, 2020 | 88 | qPCR | E N RdRP | Nasopharyngeal or mid-turbinate oropharyngeal swabs | Patients tested for SARS-CoV-2 | Unspecified | Fluorescence emitted by TaqMan probes | RNA extraction by MagNApure 96 DNA and Viral NA Small Volume, CT/NG extraction protocol, EasyMAG extraction reagents | Cepheid GeneXpert systems using the Xpert Xpress SARS-CoV-2 test |
| Wozniak, 2020 | 50 | qPCR | N1 N2 | Nasopharyngeal swabs | Outpatients | Internal controls using human RNase P gene | Fluorescence emitted by TaqMan probes | Acid pH method of RNA extraction using TaqMan qPCR | StepOnePlus Real-Time PCR System (Applied Biosystems) for both index and reference qPCR tests |
| X. Lu, 2020 | 2,923 | qPCR | N1 N2 N3 | Pharyngeal swabs Sputum Bronchoalveolar aspirate Etc. | Suspected individuals with COVID-19 Close contacts Individuals from abroad COVID-19 confirmed patients | Internal controls using human RNase P gene | Fluorescence emitted by TaqMan probes | RNA extraction by the EZ1 DSP Virus Kit (QIAGEN) | TaqPath 1-Step RT-qPCR Master Mix, CG (Thermo Fisher Scientific) in 96-well plates on Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher Scientific) |

| | | | | | | | | | |
|------------------|-----|------|------------|----------------------------|--------------------------|---|---|--|---|
| Xiao, 2020 | 25 | qPCR | ORF1b N | Throat swabs Sputum | Suspected COVID patients | Positive controls using plasmid pEasy-T1 (TransGen Biotech, Beijing, China) | Fluorescence emitted by TaqMan probes | RNA extraction by NucliSens easyMag apparatus (bioMérieux, MarcyL'Etoile, France) | TaqMan real-time RT-PCR assays using TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific, MA, USA) on Bio-Rad instrument (Bio-Rad CFX96, CA, USA) for both index and reference qPCR tests |
| Yip, 2020 | 213 | qPCR | N RdRp | Pharyngeal swabs Saliva | Suspected COVID patients | Negative and positive controls | Fluorescence emitted by sequence-specific probes | RNA extraction by NucliSENS easyMAG extraction system (bioMérieux, Marcy-l'Étoile, France) | QuantiNova Probe RT-PCR Kit (QIAGEN, Hilden, Germany) for both index and reference qPCR tests |
| Zhen, 2020 | 270 | qPCR | S | Nasopharyngeal swabs | Unspecified | Internal controls using human RNase P gene | Fluorescence emitted by TaqMan probes | RNA extraction by NucliSENS easyMag platform (BioMérieux, Durham, NC) | TaqPath 1-step RT-qPCR kit (Catalog no. A15299, Thermo Fisher Scientific) for both index and reference qPCR tests |
| Alekseenko, 2020 | 184 | LAMP | ORF1ab | Nasopharyngeal swabs | Unspecified | Positive controls No-template control | Colorimetric reading visualized by Eva Green dye Concentration measured by Qubit (Thermo Fisher Scientific) | RNA extraction by Ampure XP beads (Beckman Coulter) | In-house master mix |

| | | | | | | | | | |
|------------|-----|--------------------------------|------------|---|---|--|--|--|--|
| Ali, 2020 | 24 | LAMP coupled with CRISPR-Cas12 | N E | Nasopharyngeal swabs | COVID patients tested positive and negative | Positive controls using synthetic RNA from Twist Bioscience No-template control | End-point fluorescence detection was monitored using a Tecan plate reader (Tecan 200) | RNA extraction by QIAquick Gel Extraction kit | In-house SARS-CoV-2 testing kit for LAMP |
| Ben, 2020 | 182 | Direct LAMP qPCR | N E | Throat and nose swabs | Unspecified | No-template control, positive and negative control | Colorimetric reading using phenol red | RNA extraction by nucleic acid extraction systems (easyMAG/EMAG (Biomerieux), mag-LEAD 5bL (Precision System Science) or MagEx (STARlet) for reference qPCR test | Allplex 2019-nCoV (See-gene) or real-time fluorescent RTPCR Kit for Detecting SARS-2019-nCoV (BGI) for qPCR WarmStart Colorimetric LAMP 2X Master Mix (New England BioLabs for LAMP |
| Chow, 2020 | 366 | LAMP qPCR | ORF3a E | Pharyngeal swabs Sputum | Confirmed hospitalized COVID patients | Positive and negative controls | Color change from pink to yellow indicates a positive result | RNA extraction by QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany) | Superscript III Platinum One-Step qRT-PCR kit (Thermo Fisher Scientific, Waltham, USA) in a LightCycler 480 real-time PCR system (Roche, Risch-Rotkreuz, Switzerland for qPCR mL of Warmstart colorimetric LAMP 2 × Mastermix for LAMP |
| Dao, 2020 | 768 | LAMP LAMP Sequencing qPCR | N | Nasopharyngeal swabs Oropharyngeal swabs | Unspecified | RNA-positive control for the N gene from fragment of SARS-CoV-2 Positive control plasmid | Colorimetric reading using phenol red; Absorbance measurement with Spark Cyto at 434 and 560 nm for LAMP | RNA extraction by QIAGEN for qPCR No RNA extraction for swab-to-RT-LAMP | TIB MOLBIO Syntheselabor for qPCR; WarmStart™ Colorimetric LAMP 2X Master Mix for LAMP |

| | | | | | | | | | |
|-----------------|-----|-------------------------------|------------------|---|--|--|---|---|--|
| Flynn, 2020 | 62 | Direct LAMP qPCR | N1 N2 | Nasal swabs Throat swabs | Emergency room patients (Both previously diagnosed as posi- tive and negative) | Control using pure RNA | Colorimetric read- ing using pH sensi- tive dye | RNA extraction by au- tomated NucliSENSE easyMAG or magLEAD automated extraction platform | 2019-nCoV detection kit, Seegene, CA, USA for qPCR; WarmStart® Colorimetric L AMP 2X Master Mix for LAMP |
| Fowler, 2020 | 315 | Regular LAMP DirectLAMP | ORF1ab E | Nasopharyngeal swabs Oropharyngeal swabs Saliva | Adult inpatients | Genesig®COVID- 19 positive control Negative extraction control No template control | Opti-RT reverse transcriptase and a proprietary fluores- cent dsDNA inter- calating dye | RNA extraction by Maxwell®RSC Viral Total Nucleic Acid Pu- rification Kit (Promega UK Ltd., Southamp- ton, UK) | COVID-19 genesig Real- Time PCR assay (Pri- merdesign Ltd, Chandler's Ford, UK) for qPCR; OptiGene Ltd. (Hor- sham, UK) COVID- 19_RT-LAMP kits and RT-LAMP Isothermal Mastermix for LAMP |
| Haq, 2020 | 84 | LAMP | ORF1ab N S | Nasopharyngeal swabs | Suspected COVID patients | Unspecified | Color change from pink to yellow color indicates a positive result | RNA extraction by TANBead Nucleic Acid Extractor (model SLA-16/32) | Unspecified kit for qPCR WarmStart Colorimetric LAMP 2X Master Mix (New England Biolabs) for LAMP |
| Hu, 2020 | 481 | LAMP qPCR | ORF1ab N S | Nasopharyngeal swabs Sputum | Inpatients with clinical-radiologi- cal suspicion of COVID-19 asymptomatic COVID-19 carrier | No template con- trols | Visual color change of fluorescent light in response to UV excitation from purple to blue; by the laddering pattern of bands | ABI COVID-19 QuantStu- dio Dx real-time PCR sys- tem (Applied Biosystems, USA) for qPCR In-house solution mix for LAMP | |

| | | | | | | | | | |
|-------------------|-----|---|-------------------------------|----------------------|--|---|--|---|---|
| Huang, 2020 | 16 | LAMP qPCR | ORF1ab N1 N15 E S | Throat swabs | Unspecified | SARS-CoV-2 Positive control plasmid | Fluorescent dye from New England Biolabs (NEB) | RNA extraction by RNA extraction kit, Health Biomed | 2019-nCoV RT-PCR kit, Shanghai ZJ Bio-Tech for qPCR; Warm-Start™ LAMP 29 Master Mix, NEB for LAMP |
| Jiang, 2020 | 260 | LAMP qPCR | N | Sputum | Inpatients Outpatients | Unspecified | Unspecified | RNA extraction by EZ-10 Spin Column Viral Total RNA Extraction Kit (Sangon Biotech Co., Ltd. Shanghai, China) | NMPA RT-PCR kit from Shanghai BioGerm Medical Biotechnology Co. Ltd. And NMPA RT-PCR kit from DAAN Gene Co., Ltd for qPCR In-house solution mix for LAMP |
| Kitagawa, 2020 | 76 | LAMP qPCR | N | Nasopharyngeal swabs | Suspected COVID patients | Positive and negative controls | High turbidity under natural light after indicates a positive result | RNA extraction by QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) | Unspecified kit for qPCR Loopamp2019-nCoV (Eiken) for LAMP |
| Lalli, 2020 | 30 | LAMP qPCR | ORF1ab N | Saliva | Individuals tested COVID-19 positive or negative | Saliva-only control as negative control | Visual change of color from red to yellow Color intensity measured by Bio-Tek Epoch microplate spectrophotometer Fluorescence emitted by DNA-binding dye SYTO 9 (ThermoFisher) | No extraction for both LAMP and qPCR | Quantstudio 3 and 6 Real-Time PCR systems (ThermoFisher) for qPCR WarmStart Colorimetric LAMP 2X Master Mix (NEB, M1800L) and QuantStudio 3 or 6 RT-PCR system for LAMP |
| Lamb, 2020 | 60 | Regular LAMP Direct LAMP qPCR | ORF1ab N1 N2 | Nasopharyngeal swabs | Patients diagnosed as positive or negative by qPCR | Water as no template control | Visual change of color from orange to Yellow using SYBR green I (Life Technologies) | RNA extraction by instruments by Beaumont's Clinical Laboratory Improvement Amendments (CLIA)-licensed Clinical Reference Lab | CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel on a Maxwell Instrument for qPCR In-house solution mix for LAMP |

| | | | | | | | | | |
|-----------------|-----|-----------|------------|--|---|---|---|---|--|
| Lee, 2020 | 157 | LAMP | N1 | Nasopharyngeal swabs | Unspecified | Water as no template control | Fluorescence emitted by Taq-Man probes for qPCR Unspecified method for LAMP | RNA extraction by QIAsymphony DSP Virus/Pathogen Mini Kit (Qiagen, Cat No. 937036) for qPCR Solid-phase reversible immobilisation (SPRI) on carboxylated paramagnetic beads (Sera-Mag Magnetic Speed Beads, from GE Healthcare) for LAMP | Dried Reverse Transcriptase Isothermal Mastermix (Optigene, ISO-DR004-RT) for LAMP |
| Lu, 2020 | 56 | LAMP qPCR | N | Throat swabs | Suspected COVID patients Control populations | No-template control (NTC) | Visual detection with cresol red from NEB | RNA extraction kit, Liferiver, Shanghai | SARS-CoV-2 RT-qPCR kit, Liferiver Bio; Light-Cycler 96 real-time PCR System for LAMP |
| Mohon, 2020 | 100 | LAMP qPCR | RdRp S E N | Nasopharyngeal swabs (n=100) Contrived samples (n=24) | Unspecified | External control using primers against bacteriophage MS2 | 50X SYBR safe and CFX-96 real-time PCR detection system; measured in relative fluorescence units (RFU) per minute | RNA extraction by Promega SV Total RNA Isolation System | CFX-96 real-time PCR detection system Solution mix with Warmstart® Rtx Reverse Transcriptase (New England Biolab, Whitby, ON) and Bst 2.0 Warmstart® DNA Polymerase (New England Biolab, Whitby, ON) for LAMP |
| Papadakis, 2020 | 89 | LAMP qPCR | N E RdRp | Nasopharyngeal swabs | Suspected COVID patients | Positive controls using human RNase P gene Negative controls | Colorimetric reading using phenol red | RNA extraction by QIAamp DNA Micro Kit (Qiagen) | NucliSens easyMAG automated system and Benchtop equipment for qPCR WarmStart 2 × Master Mix (New England Bi-oLabs) for LAMP |

| | | | | | | | | | |
|-------------------|-----|------------------------------------|-----------------------------------|---------------------------------------|--|---|---|--|--|
| Rödel, 2020 | 43 | RNA LAMP Direct LAMP qPCR | RdRP M E N | Pharyngeal swabs | Unspecified | 30 samples from patients tested by qPCR as external control | Measured by real-time fluorescence detection using a DNA intercalating dye | RNA extraction by QIAasympo DSP Virus/Pathogen Mini Kit for qPCR; QIAasympo DSP Virus/Pathogen Mini Kit (Qiagen, Hilden, Germany) for LAMP | Allplex™ 2019-nCoV assay for qPCR; Variplex™SARS-CoV-2 RT-LAMP assay and Allplex™ assay for LAMP |
| Rohaim, 2020 | 99 | AI-LAMP qPCR | N RdRp | Nasopharyngeal swabs | Suspected COVID patients | Internal control using miR-cel-miR-39-3p | Color change from pink to yellow color indicates a positive result | RNA extraction by QIAamp Viral RNA Mini kit (Qiagen, Valencia, CA, USA) | SuperScript III Platinum One-Step qRT-PCR Kit for qPCR WarmStart™ Colorimetric LAMP 2X Master Mix (New England Biolabs, Hitchin, UK) for LAMP |
| Schermer, 2020 | 171 | LAMP | ORF1a ORF3a ORF7a N M | Nasopharyngeal swabs | Symptomatic pa-tients | Positive and negative controls | Color change from pink to yellow color indicates a positive result | RNA extraction by automated MagNA Pure 96 system (Roche) | RealStar SARS-CoV-2 RT-PCR kit 1.0 for qPCR WarmStart Colorimetric RT-LAMP mix (NEB) for LAMP |
| Yan, 2020 | 130 | LAMP qPCR | ORF1ab S | Swabs Bronchoalveolar lavage fluid | Patients with pneumonia and suspected SARS-CoV-2 infection | Negative control using distilled water; Positive control using pseudo-virus | Colorimetric reading using fluorescent calcein and turbidity Monitoring by Loopamp real-time turbidimeter | RNA extraction by QIAamp Viral RNA Mini Kits | Real-time RT-PCR kit, BGI PathoGenesis Pharmaceutical Technology for qPCR; Loopamp RNA amplification kit, Eiken Chemical for LAMP |

| | | | | | | | | | |
|---------------|-----|----------------|-----------------------|--------|---|--------------------------------------|---|-------------|--|
| Yang, 2020 | 463 | Direct LAMP | ORF1ab ORF1e N2 | Saliva | Healthy individu- als Infected individu- als | RNaseP for positive control 10 | Colorimetric read- ing using phenol red | Unspecified | NEB's WarmStart LAMP 2x Master Mix for LAMP |
|---------------|-----|----------------|-----------------------|--------|---|--------------------------------------|---|-------------|--|

Supplementary Table 2. Primary subgroup analysis for LAMP, dPCR, and qPCR assays using bivariate latent class model

Summary of respective pooled sensitivity and specificity of the test of interest (e.g., LAMP using nasopharyngeal swabs, LAMP using saliva, dPCR using N primer etc.) and the reference test (EUA approved PCR assays) based on the number of true false positive and negative cases reported in the 71 studies are shown below. All dPCR assays required RNA extraction. Abbreviations: CI, Confident Interval

^a Since bivariate models do not converge when the sample size is small, for subgroups with less than four included studies, univariate random-effects model was used to compute sensitivity and specificity of the test of interest assuming the reference test is the gold standard.

| Subgroups | Number of studies (N) [sample size (n)] | Pooled sensitivity of test of interest (CI) | Pooled specificity of test of interest (CI) | Pooled sensitivity of reference test (CI) | Pooled specificity of reference test (CI) |
|-----------------------|--|--|--|--|--|
| LAMP | | | | | |
| Overall | 31[3453] | 86.2% (20.7%-99.9%) | 94.3% (49.1%-100%) | 96.7% (58.7%-100%) | 87.6% (19.2%-99.9%) |
| Specimen | | | | | |
| Nasopharyngeal swabs | 10[1004] | 87.4% (55.0%-99.0%) | 94.8% (69.7%-99.9%) | 99.1% (96.0%-99.9%) | 98.9% (96.2%-99.9%) |
| Oropharyngeal swabs | 11[1046] | 84.5% (18.3%-99.9%) | 94.7% (53.3%-100%) | 95.4% (66.7%-99.9%) | 91.5% (31.5%-99.9%) |
| Saliva | 5[773] | 69.0% (1.0%-99.8%) | 86.8% (2.3%-100%) | 84.5% (3.1%-100%) | 72.1% (1.6%-99.9%) |
| Sputum | 7[513] | 74.6% (0.4%-99.4%) | 89.4% (0.6%-100%) | 88.5% (0.4%-100%) | 83.4% (0.1%-100%) |
| RNA extraction | | | | | |

| | | | | | |
|------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| With RNA extraction | 17[2445] | 85.7% (24.1%-99.8%) | 93.7% (36.8%-100%) | 95.4% (33.8%-100%) | 94.3% (33.5%-100%) |
| Without RNA extraction | 14[1008] | 85.0% (39.1%-99.3%) | 99.1% (96.6%-100%) | 98.6% (94.7%-99.9%) | 85.1% (51.5%-98.1%) |
| Primer/probe Set | | | | | |
| ORF1ab primer | 6[1008] | 80.8% (9.7%-99.8%) | 96.4% (55.0%-100%) | 95.5% (45.2%-100%) | 91.8% (26.8%-99.9%) |
| N primer | 10[1136] | 83.3% (29.2%-98.7%) | 95.2% (27.3%-100%) | 94.6% (44.9%-100%) | 89.7% (4.6%-100%) |
| E primer | 2[146] ^a | 81.6% (71.0%-89.5%) | 100% (94.9%-100%) | - | - |
| RNA extraction method | | | | | |
| Magnetic beads | 5[408] | 91.5% (73.7%-98.7%) | 99.0% (96.5%-99.9%) | 98.7% (95.4%-99.9%) | 93.6% (68.3%-99.8%) |
| Silica spin column | 19[1634] | 75.7% (0.2-99.9%) | 87.0% (0.5%-100%) | 88.9% (0.5%-100%) | 85.7% (0.1%-100%) |
| dPCR | | | | | |
| Overall | 15[783] | 95.8% (54.9%-100%) | 73.8% (0.9%-100%) | 85.0% (12.4%-99.8%) | 94.8% (32.9%-100%) |
| Specimen | | | | | |
| Pharyngeal swabs | 7[459] | 95.1% (66.4%-99.8%) | 86.0% (35.1%-99.6%) | 82.9% (22.3%-99.5%) | 97.6% (86.1%-99.9%) |
| Saliva | 3[152] ^a | 89.7% (75.8%-97.1%) | 77.0% (68.1%-84.4%) | - | - |
| Sputum | 2[98] ^a | 100% (93.4%-100%) | 88.6% (75.4%-96.2%) | - | - |
| Primer/probe Set | | | | | |
| ORF1ab primer | 11[544] | 99.4% (97.6%-100%) | 74.7% (1.8%-100%) | 96.5% (87.5%-99.9%) | 99.5% (97.8%-100%) |
| N primer | 15[783] | 95.8% (54.9%-100%) | 73.8% (0.9%-100%) | 85.0% (12.4%-99.8%) | 94.8% (32.9%-100%) |
| RNA extraction method | | | | | |
| Silica spin column | 8[536] | 96.9% (86.4%-99.9%) | 87.7% (14.8%-99.8%) | 76.1% (7.6%-99.8%) | 98.1% (92.4%-99.9%) |
| Automatic | 4[173] | 98.3% (92.5%-100%) | 95.8% (79.8%-99.8%) | 93.8% (72.6%-99.7%) | 98.9% (95.3%-99.9%) |
| qPCR | | | | | |

| | | | | | |
|------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Overall | 25[3667] | 93.4% (60.9%-99.9%) | 93.1% (47.1%-100%) | 99.5% (98.1%-100%) | 99.2% (97.2%-99.9%) |
| Specimen | | | | | |
| Pharyngeal swabs | 13[2250] | 88.0% (2.8%-100%) | 90.9% (4.3%-100%) | 88.1% (2.0%-99.4%) | 90.4% (1.4%-100%) |
| Saliva | 10[1175] | 84.7% (1.2%-99.9%) | 84.3% (0.2%-100%) | 86.3% (0.7%-100%) | 86.3% (0.7%-100%) |
| RNA extraction | | | | | |
| With RNA extraction | 19[3230] | 91.6% (11.7%-100%) | 89.3% (7.3%-100%) | 92.5% (5.9%-100%) | 91.3% (6.6%-100%) |
| Without RNA extraction | 6[437] | 87.9% (63.5%-98.6%) | 95.6% (80.3%-99.7%) | 96.3% (85.7%-99.7%) | 94.5% (46.5%-99.8%) |
| Primer/probe Set | | | | | |
| ORF1ab primer | 5[1369] | 84.7% (2.6%-100%) | 84.6% (0.0%-100%) | 81.9% (0.1%-100%) | 85.9% (0.2%-100%) |
| N primer | 12[899] | 84.8% (0.0%-100%) | 80.8% (0.1%-100%) | 87.3% (0.5%-100%) | 84.9% (0.0%-100%) |
| E primer | 11[2442] | 71.5% (0.3%-100%) | 74.0% (0.1%-100%) | 75.3% (0.1%-100%) | 72.4% (0.0%-100%) |
| RNA extraction method | | | | | |
| Magnetic beads | 7[1170] | 94.4% (69.9%-99.9%) | 99.6% (98.6%-100%) | 99.0% (96.4%-99.9%) | 98.9% (95.8%-99.9%) |
| Silica spin column | 10[1805] | 98.4% (19.8%-100%) | 84.8% (3.0%-99.8%) | 74.0% (3.0%-99.8%) | 91.3% (61.8%-99.6%) |
| Automatic | 2[224] ^a | 96.7% (88.5%-99.6%) | 91.5% (86.1%-95.3%) | - | - |

Supplementary Table 3. dAUC and P values of LAMP, dPCR, and qPCR

Difference in AUC (dAUC) and P values of LAMP, dPCR, and qPCR. A P value of 0.05 or less (highlighted in bold) indicates statistical significance i.e., significant difference between two subgroups.

| | dAUC | P value |
|---------------------------------|--------------------------|--------------|
| LAMP | | |
| Specimen | | |
| Pharyngeal swabs vs. saliva | -0.026 (-0.088, -0.011) | 0.017 |
| Pharyngeal swabs vs. sputum | -0.028 (-0.083, 0.080) | 0.281 |
| Saliva vs. sputum | -0.002 (-0.020, 0.125) | 0.765 |
| Primer/probe set | | |
| ORF1ab vs. N | 0.017 (-0.012, 0.070) | 0.204 |
| ORF1ab vs. E | -0.00044 (-0.034, 0.053) | 0.843 |
| N vs. E | -0.017 (-0.075, 0.035) | 0.273 |
| RNA extraction | | |
| With vs. without RNA extraction | 0.0056 (-0.0244, 0.0601) | 0.526 |
| RNA extraction method | | |
| Magnetic beads vs. spin column | 0.019 (-0.035, 0.060) | 0.254 |
| dPCR | | |
| Specimen | | |
| Pharyngeal swabs vs. saliva | -0.029 (-0.081, -0.005) | 0.032 |
| Pharyngeal swabs vs. sputum | -0.031 (-0.079, 0.094) | 0.32 |
| Saliva vs. sputum | -0.002 (-0.020, 0.125) | 0.765 |
| Primer/probe set | | |
| ORF1ab vs. N | 0.015 (0.011, 0.097) | 0.045 |
| RNA extraction method | | |
| Spin column vs. automatic | -0.039 (-0.148, 0.011) | 0.093 |
| qPCR | | |

| | | |
|---------------------------------|-------------------------|--------------|
| Specimen | | |
| Pharyngeal swabs vs. saliva | 0.028 (-0.0046, 0.109) | 0.08 |
| Primer/probe set | | |
| ORF1ab vs. N | 0.0059 (-0.0467, 0.051) | 0.541 |
| ORF1ab vs. E | 0.0066 (-0.060, 0.052) | 0.646 |
| N vs. E | 0.00068 (-0.043, 0.040) | 0.859 |
| RNA extraction | | |
| With vs. without RNA extraction | 0.0367 (-0.0173, 0.134) | 0.203 |
| RNA extraction method | | |
| Magnetic beads vs. spin column | 0.035 (0.007, 0.159) | 0.031 |

Supplementary Table 4. Sensitivity, specificity, and DOR in secondary subgroup analysis by clustering

Pink represents dPCR, green for qPCR, and blue for LAMP. Since there were less than 4 studies testing on saliva samples in each cluster, only results for swab studies were shown. Swabs referred to pharyngeal swabs. The results showed that the three nucleic-acid tests generally performed better with *ORF1ab* than with *N* primer. All studies used WHO reference tests.

| | | dPCR | qPCR | LAMP | | | | |
|---------------------|---------------|-------|----------------------------------|---------------------------------|-------------------------------|--------------------------------|--------------------------------|-----------------------------|
| With RNA extraction | DOR | Swabs | 2082.41 (353.44- 12269.35) | 2053.37 (680.75- 6193.62) | 931.31 (94.51- 1591.10) | 555.18 (107.73- 2861.12) | 473.53 (104.36- 2148.54) | 96.59 (18.36- 508.26) |
| | Sensitivity % | Swabs | 97.5 (90.5- 99.4) | 97.5 (88.0- 99.5) | 91.5 (76.1- 97.3) | 96.0 (88.7- 98.6) | 93.8 (88.6- 96.7) | 80.2 (54.4- 93.3) |
| | Specificity % | Swabs | 97.9 (94.5- 99.2) | 97.1 (89.3- 99.3) | 98.4 (93.3- 99.6) | 96.0 (87.9- 98.8) | 93.1 (80.5- 97.8) | 94.1 (84.6- 97.9) |
| | | | ORF1ab | | | N | | |

Supplementary Table 5. Summary of primer-probe sets for 66 studies

Primer sequences provided by the 66 studies, shown in 5'-3'. Abbreviation – F, Forward; B, Backward; FIP, Forward Inner Primer; BIP, Backward Inner Primer

| Study | Probe/Primer Sets |
|------------------|---|
| dPCR | |
| Abasiyanik, 2020 | <p>RnaseP probe/primers sets for index dPCR test <i>N1, N2 or RnaseP probe/primers sets (IDT 2019-nCov CDC EUA) for reference qPCR test</i> <i>Primer sequences not provided</i> <i>Primers targeting RdRp</i> <i>Forward: 5'- GACTTTGTGAATGAGTTTACGC-3'</i> <i>Reverse: 5'- AGCCACTAGACCTTGAGATGC-3'</i> <i>FAM Probe: 5'- CACACAACAGCATCGTCAGA-3'</i> <i>housekeeping gene RNase P: HEX</i> <i>Forward: 5'- AGATTGGACCTGCGAGCG-3'</i> <i>Reverse: 5'- GAGCGGCTGTCTCCACAAGT -3'</i> <i>HEX Probe: 5'- TTCTGACCTGAAGGCTCTGCGCG-3'</i> <i>CN-CDC-1 (ORF1ab) (FAM)</i> <i>Forward: "CCCTGTGGGTTTTACACTA"</i> <i>Reverse: "ACGATTGTGCATCAGCTGA"</i> <i>Probe: "CCGTCTGCGGTATGTGGAAAGGTTATGG"</i> <i>CN-CDC-2 (ORF1a) (FAM)</i> <i>Forward: "GGGGAACCTCTCCTGCTAT"</i> <i>Reverse: "CAGACATTGCTCTCAAGCTG"</i> <i>Probe: "TTGCTGCTGCTTGACAGATT"</i> <i>RdRP_SARSr (RdRP) (HEX)</i> <i>Forward: "GTGARATGGTCATGTGTGGCGG"</i> <i>Reverse: "CARATGTTAAASACACTATTAGCATA"</i> <i>Probe: "CCAGGTGGWACRTCATCMGGTGATGC"</i> <i>2019-nCoV_N1 (N) (HEX)</i> <i>Forward: "GACCCCAAATCAGCGAAAT"</i> <i>Reverse: "TCTGGTTACTGCCAGTTGAATCTG"</i> <i>Probe: "ACCCCGCATTACGTTGGTGGACCC"</i> <i>nCoV_IP2 (RdRP) (HEX)</i> <i>Forward: "ATGAGCTTAGTCCTGTTG"</i> <i>Reverse: "CTCCCTTGTTGTGTTGT"</i> <i>Probe: "AGATGTCTTGCTGCCGGTA"</i> <i>nCoV_IP4 (RdRP) (FAM)</i> <i>Forward: "GGTAACCTGGTATGATTTCG"</i></p> |
| Cassinari, 2020 | |

Reverse: "CTGGTCAAGGTTAATATAAGG"
Probe: "TCATACAAACCACGCCAGG"

Dang, 2020

ORF1ab, N (BioGerm Medical Biotechnology Co., Ltd., Shanghai, China)
Primer sequences not provided

Deiana, 2020

2019-nCoV CDC dPCR triplex probe (N1, N2)
Primer sequences not provided

Dong, 2020

ORF1ab, N probe/primers sets (according to Chinese CDC)
Primer sequences not provided

N probe/primers sets (in-house)

Primers targeting N gene

Forward: "CAACTCCAGGCAGCAGTAGGG"

Reverse: "CTCTCAAGCTGGTTCAATCTGTCA"

Probe: "CY5-AAGAGCAGCATACCG-MGB"

Liu, 2020

Internal control

Forward: "GGGCTCTTGCAAGGTCTCTC"

Reverse: "CCAGCAAGAGTCCCCATCC"

Probe: "VIC-AGCCCCTTGTGGACATAGGGTTT-BHQ1"

Oberding, 2020

E probe/primers sets (based on Corman et al.)

Primer sequences not provided

ORF1ab, N (RainSure Scientific) (according to Chinese CDC)

Primers targeting ORF1ab

Forward: "CCCTGTGGGTTTACACTTAA"

Reverse: "ACGATTGTGCATCAGCTGA"

Probe: "FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1"

Suo, 2020

Primers targeting N

Forward: "GGGGAACCTCTCTGCTAGAACAT"

Reverse: "CAGACATTGCTCTCAAGCTG"

Probe: "HEX-TTGCTGCTGCTGACAGATT-TAMRA"

Primers targeting ORF1ab gene

Forward: "TGGGGYTTACRGTAACCT"

Reverse: "AACRCGCTAACAAAGCACTC"

Probe: "TAGTTGTATGCWATCATGACTAG"

Primers targeting N gene

Forward: "TAATCAGACAAGGAACGTGATTA"

Reverse: "CGAAGGTGTGACTTCCATG"

Probe: "GCAAATTGTGCAATTGCGG"

Y. Jiang, 2020

ORF1ab, N probe/primers sets

Primer sequences not provided

qPCR

Altawalah, 2020

Primer targeting ORF1ab, N, and S genes
Primer sequences not provided

Anderson, 2020

Primer targeting N gene
Primer sequences not provided

Primers targeting E according to Corman et al., 2020

Forward "ACAGGTACGTTAATAGTTAACAGCGT"

Reverse "ATATTGCAGCAGTACGCACACA"

Probe "FAM-ACACTAGGCC/ZEN/ATCCTTACTGCGCTTCG-ABkFQ"

Primers targeting RdRP according to Corman et al., 2020

Forward "GTGARATGGTCATGTGTGGCGG"

Reverse "CARATGTTAAASACACTATTAGCATA"

Probe 1 "FAM-CCAGGTGGW/ZEN/ACRTCATCMGGTGATGC-ABkFQ"

Probe 2 "FAM-CAGGTGGAA/ZEN/CCTCATCAGGAGATGC-ABkFQ"

Primers targeting N according to Corman et al., 2020

Forward "CACATTGGCACCCGCAATC"

Reverse "GAGGAACGAGAAGAGGGCTTG"

Probe "FAM-ACTTCTCA/ZEN/AGGAACAACTTGCCA-ABkFQ"

Barra, 2020

Primers targeting N1 according to the Centers for Disease Control (CDC)

Forward "GACCCCAAAATCAGCGAAAT"

Reverse "TCTGGTTACTGCCAGTTGAATCTG"

Probe "FAM-ACCCCCCAT/ZEN/TACGTTTGGTGGACC-ABkFQ"

Primers targeting N2 according to the Centers for Disease Control (CDC)

Forward "TTACAAACATTGGCCGCAA"

Reverse "GCGCGACATTCGAAGAA"

Probe "FAM-ACAATTG/ZEN/CCCCAGCGCTTCAG-ABkFQ"

Primers targeting N3 according to the Centers for Disease Control (CDC)

Forward "GGGAGCCTTGAATAACACAAAAA"

Reverse "TGTAGCACGATTGCAGCATTG"

Probe "FAM-AYCACATTG/ZEN/GCACCCGCAATCCTG-ABkFQ"

Primers targeting N genes

2019-nCoV_N1-F 2019-nCoV_N1 forward primer 50-GAC CCC AAA ATC AGC GAA AT-30

2019-nCoV_N1-R 2019-nCoV_N1 reverse primer 50-TCT GGT TAC TGC CAG TTG AAT CTG-30

2019-nCoV_N1-P 2019-nCoV_N1 probe 50-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1-30

2019-nCoV_N2-F 2019-nCoV_N2 forward primer 50-TTA CAA ACA TTG GCC GCA AA-30

2019-nCoV_N2-R 2019-nCoV_N2 reverse primer 50-GCG CGA CAT TCC GAA GAA-30

2019-nCoV_N2-P 2019-nCoV_N2 probe 50-FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1-30

2019-nCoV_N3-F 2019-nCoV_N3 forward primer 50-GGG AGC CTT GAA TAC ACC AAA A-30

2019-nCoV_N3-R 2019-nCoV_N3 reverse primer 50-TGT AGC ACG ATT GCA GCA TTG-30

2019-nCoV_N3-P 2019-nCoV_N3 probe 50-FAM-AYC ACA TTG GCA CCC GCA ATC CTG-BHQ1-30

Bruce, 2020

Chan, 2020

Primers targeting RdRp/HeL, S, or N genes

Primer sequences not provided

Primer targeting E gene (same as in Corman et al.)

E_Sarbeco_Forward ACAGGTACGTTAATAGTTAATAGCGT

E_Sarbeco_Probe1 FAM-ACACTAGCCATCCTTACTGCCCTTCG-BHQ

E_Sarbeco_Reverse ATATTGCAGCAGTACGCACACA

Dorlass, 2020

Primers targeting N genes

Primer sequences not provided

Freire, 2020

Primers targeting N genes

Primer sequences not provided

Garcia, 2020

Primer targeting E gene

E_Sarbeco_Forward1 "ACAGGTACGTTAATAGTTAATAGCGT" 0.4uM

E_Sarbeco_Reverse2 "ATATTGCAGCAGTACGCACACA" 0.4uM

E_Sarbeco_Probe1 "FAM/ZEN-ACACTAGCCATCCTTACTGCCCTTCG- IaBkFQ" 0.2uM

Hasan, 2020

Internal control

MS2-TM3-Forward "GGCTGCTCGCGGATAACCC" 0.2uM

MS2-TM3-Reverse "TGAGGGAATGTGGGAACCG" 0.2uM

MS2-TM2JOE "JOE/ZEN-ACCTGGGTTCCGTCTGCTCGT- IaBkFQ" 0.1uM

Jung, 2020

Primers targeting N and RdRP/ORF1 using primer sets from institutes including China CDC, HKU, Japan NIID, ThailandNIH, US CDC, and Charite

Kandel, 2020

Primers targeting E genes

Primer sequences not provided

Primers targeting E gene (based Corman et al.)

Forward "ACAGGTACGTTAATAGTTAATAGCGT"

Reverse "ATATTGCAGCAGTACGCACACA"

Probe "FAM-ACACTAGCCATCCTTACTGCCCTTCG-BHQ"

Primers targeting E gene (based Corman et al.)

Forward "ACAGGTACGTTAATAGTTAATAGCGT"

Reverse "ATATTGCAGCAGTACGCACACA"

Probe "FAM-ACACTAGCCATCCTTACTGCCCTTCG-BHQ"

Primers targeting E gene

CoV-E-Forward "CTTTTCTTGCCTTCGTGGTATTCT" 400 nM

CoV-E-Reverse "TACAAGACTCACGTTAACATATTGCA" 400 nM

CoV-E-Probe "FAM-CTAGCCATCCTTACTGCCCTTCGATTGTG-BHQ" 200 nM

Klein, 2020

Internal control targeting HBV-SynQ

HBV-Taq1 "CAACCTCCAATCACTCACCAAC" 200 nM

HBV-Taq2 "ATATGATAAAACGC GCAGACAC" 200 nM

HBV-IC "Cy5-CTGCCGAGCTGACTA-BHQ" 200 nM

Konrad, 2020

Primers targeting N2 and E genes

Primer sequences not provided

Lübke, 2020

Merindol, 2020

Primers targeting N, E, S, and RdRp genes
Primer sequences not provided

Moreno-Contreras, 2020

Primers targeting E genes
Primer sequences not provided

Primers for internal control (EXO)

Forward "GGCGGAAGAACAGCTATTGC"

Reverse "GGAACCTAAGACAAGTGTGTTATGG"

Probe "Cy5-ACAATTGCCCCAGCGCTTCAG-BHQ"

Complete probe and primer sequences can be found in the CDC SARS-CoV-2 protocol

<https://www.fda.gov/media/134922/download>

Perchetti, 2020

Primers targeting ORF1a, E, and N genes

Primer sequences not provided

Pujadas, 2020

nCOV_N1 Forward Primer Aliquot (CN 10006830), nCOV_N1 Reverse Primer Aliquot (CN 10006831), nCOV_N1 Probe Aliquot (CN 10006832),

nCOV_N2 Forward PrimerAliquot (CN 10006833), nCOV_N2 Reverse Primer Aliquot (CN 10006834), nCOV_N2 Probe Aliquot (CN10006835), RNase P Forward Primer Aliquot (CN 10006836), RNase P Reverse Primer Aliquot (CN10006837), RNase P Probe Aliquot (CN 10006838) 2019-nCoV_N_Positive Control (IDT CN 10006625)

Primer sequences not provided

Nested PCR

nForward1 AYTCAATGAGTTATGAGGAYCAAGATGC 400 nM

nReverse1 GACATCAGCATACTCCTGATTWGGATG 400 nM

nForward2 TAGTACTATGACMAATAGACAGTTYCATC 500 nM

nReverse2 CCTTTAGTAAGGTCAGTCTCAGTCC 500 nM

Charité-RdRP

Ratcliff, 2020

RdRp_SARSr-Forward GTGARATGGTCATGTGTGGCGG 600 nM

RdRp_SARSr-Probe2 FAMCAGGTGGAACCTCATCAGGAGATGCBHQ 100 nM

RdRp SARSr-Reverse CAAATGTTAARACACTATTAGCATA 800 nM

CDC N1

2019-nCoV_N1-Forward GACCCCAAAATCAGCGAAAT 500 nM

2019-nCoV_N1-Probe FAM-ACCCCGCATTACGTTGGACCBHQ 125 nM

2019-nCoV_N1-Reverse TCTGGTTACTGCCAGTTGAATCTG 500 nM

Sun, 2020

Primers targeting ORF1ab, N, and E genes

Primer sequences not provided

Vaz, 2020

Primers targeting E and RdRp genes

Primer sequences not provided

Visseaux, 2020

Primer sets designed by Corman et al.

Primers targeting N genes

Primers and probe for N1

Vogels, 2020

N1-Forward: GACCCCAAAATCAGCGAAAT

N1-Reverse: TCTGGTTACTGCCAGTTGAATCTG

N1-Probe: FAM-ACCCCGCATTACGTTGGACCBHQ-IBFQ

Primers and probe for N2

N2-Forward: TTACAAACATTGGCCGCAAA

N2-Reverse: GCGCGACATTCCGAAGAA

N2-Probe: HEX-ACAATTGCCCCAGCGCTTCAG-IBFQ

Internal control

Primers and probe for RNase P

RP-Forward: AGATTGGACCTGCGAGCG

RP-Reverse: GAGCGGCTGTCTCCACAAGT

RP-Probe: Cy5-TTCTGACCTGAAGGCTCTGCGCG-IBRQ

Wang, 2020

Primers targeting ORF1ab and N genes

Primer sequences not provided

Wolters, 2020

Primers targeting E, N1, and RdRP genes

Primer sequences not provided

Primers targeting N genes

Primers and probe for N1

N1-Forward: "GACCCCAAAATCAGCGAAAT"

N1-Reverse: "TCTGGTTACTGCCAGTTGAATCTG"

N1-probe: "FAM-ACCCCGCATTACGTTGGTGGACC-BHQ1"

Primers and probe for N2

N2- Forward: "TTACAAACATTGGCCGCAAA "

N2- Reverse: "GCGCGACATTCCGAAGAA"

N2-probe: "FAM-ACAATTGCCCCAGCGCTTCAG-BHQ1"

Internal control

Primers and probe for RNase P

RP2- Forward: "AGATTGGACCTGCGAGCG"

RP2- Reverse: "GAGCGGCTGTCTCCACAAGT"

RP2-probe: "FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ1"

Primers targeting N1 gene

Forward- "GACCCCAAAATCAGCGAAAT"

Reverse- "TCTGGTTACTGCCAGTTGAATCTG"

Probe- "ACCCCGCATTACGTTGGTGGACC"

Primers targeting N2 gene

Forward- "TTACAAACATTGGCCGCAAA "

Reverse- "GCGCGACATTCCGAAGAA"

Probe- "ACAATTGCCCCAGCGCTTCAG"

Wonzinak, 2020

Primers targeting N3 gene

Forward- "GGGAGCCTTGAATAACACAAAAA"

Reverse- "TGTAGCACGATTGCAGCATTG"

Probe- "AYCACATTGGCACCCGAATCCTG"

X. Lu, 2020

Primers targeting Human RNase P gene

Forward- "AGATTGGACCTGCGAGCG"

Xiao, 2020

Reverse- "GAGCGGCTGTCTCCACAAGT"
Probe- "TTCTGACCTGAAGGCTCTGCGCG"

IPBCAMS assays
Primers targeting *ORF1b* gene
Forward- "ACGGTGACATGGTACCAT"
Reverse- "CTAAGTTGGCGTATAACGCGT"
Probe- "TACACAATGGCAGACCTCGTATGC"
Primers targeting *N* gene
Forward- "AACACAAGCTTCGGCAGAC"
Reverse- "ACCTGTGTAGGTCAACCACG"
Probe- "CAGCGCTTCAGCGTTCTCGGAATGTCGC"

WHO assays
Primers targeting *ORF1b* gene
Forward- "GTGARATGGTCATGTGTGGCGG"
Reverse- "CARATGTTAAASACACTATTAGCATA"
Probe- "CAGGTGGAACCTCATCAGGAGATGC"
Primers targeting *N* gene
Forward- "CACATTGGCACCCGCAATC"
Reverse- "GAGGAACGAGAAGAGGGCTTG"
Probe- "ACTTCCTCAAGGAACACATTGCCA"

Yip, 2020

CCDC assays
Primers targeting *ORF1b* gene
Forward- "CCCTGTGGGTTTACACTTAA"
Reverse- "ACGATTGTGCATCAGCTGA"
Probe- "CCGTCTGCGGTATGTGAAAGGTTATGG"
Primers targeting *N* gene
Forward- "GGGAACTTCTCCTGCTAGAAT"
Reverse- "CAGACATTGCTCTCAAGCTG"
Probe- "TGCCTGCTGCTTGACAGATT"
In-house single-tube nested real-time RT-PCR
Primers targeting *RdRp/He* gene
Outer forward "AGGTATTGGGAACCTGAGTTTATGAGGGCTATGTACACAC"
Outer reverse "ACCTGGAGCATTGCAAACATACGGATTAACAGACAAGAC"
Inner forward "CGCATACAGTCTTRCAGGCT"
Inner reverse "GTGTGATGTTGAWATGACATGGTC"
Probe "FAM-TTAAGATGTGGTGCCTGCATACGTAGAC-lABkFQ"
Primers targeting *N* gene
Outer forward "AATTGCACAATTGCCCGAGCGCTTCA"
Outer reverse "TGCCTCAATATGCTTATTCAAGCAAAATGACTGATCTTGA"
Inner forward "GCGTTCTCGGAATGTCG"
Inner reverse "TTGGATCTTGTACATCCAATTG"
Probe "FAM-AACGTGGTTGACCTACACAGST-lABkFQ"

In-house non-nested real-time RT-PCR

Primers targeting RdRp/Hel gene

COVID-19-RdRp/Hel-Forward “CGCATACAGTCTTRCAGGCT”

COVID-19-RdRp/Hel-Reverse “GTGTGATGTTGAWATGACATGGTC”

COVID-19-RdRp/Hel-Probe “FAM- TTAAGATGTGGTGCTGCATACTAGAC -lABkFQ”

Primers targeting N gene

NIID_2019-nCOV_N_Forward2 “AAATTTGGGGACCAGGAAC”

NIID_2019-nCOV_N_Reverse 2 “TGGCAGCTGTGTAGGGTCAAC”

NIID_2019-nCOV_N_Probe2 “FAM- ATGTCGCGCATTGGCATGGA -BHQ”

Primers targeting S gene

S Gene- Forward “TCA ACT CAG GAC TTG TTC TTA C”

S Gene- Reverse “TGG TAG GAC AGG GTT ATC AAA C”

S Gene-Probe “FAM- TGG TCC CAG AGA CAT GTA TAG CAT-BHQ1b”

Primers targeting RNase P gene

RNase P RP- Forward “AGA TTT GGA CCT GCG AGC G”

RP- Reverse “GAG CGG CTG TCT CCA CAA GT”

RP-Probe “Cy5-TTC TGA CCT GAA GGC TCT GCG CG-BHQ2c”

Zhen, 2020

LAMP

Primer set targeting ORF1ab gene (iLACO) for LAMP

F3 “CCACTAGAGGAGCTACTGTA”

B3 “TGACAAGCTACAACACGT”

FIP “AGGTGAGGGTTTCTACATCACTATATTGAAACAAGCAAATTCTATGG”

BIP “ATGGGTTGGATTATCCTAAATGTGTGCGAGCAAGAACAGTG”

LF “CAGTTTTAACATGTTGCCAACC”

LB “TAGAGCCATGCCTAACATGCT”

Primer set targeting ORF1ab gene (AS1) for LAMP

F3 “CGGTGGACAAATTGTCAC”

B3 “CTTCTCTGGATTAAACACACTT”

FIP “TCAGCACACAAGCCAAAATTATCTGTGCAAAGGAAATTAGGAG”

BIP “TATTGGTGGAGCTAAACTAAAGGCCGTACAATCCCTTGAGTG”

LF “TTACAAGCTTAAAGAATGTCGAACACT”

LB “TTGAATTAGGTGAAACATTGTCACG”

Alekseenko, 2020

Primer set targeting ORF1ab gene (iLACO) for qPCR

Forward “TAATACGACTCACTATAGGGTCAATAGCCGCCACTAGA”

Reverse “AGAACCGGTGACAAGCTAC”

Primer set targeting ORF1ab gene (AS1/AS1E) for qPCR

Forward “TAATACGACTCACTATAGGGTCTGTGAAATTGTCGGTGG”

Reverse “GCTTTAGAGGCATGAGTAGGC”

Primer set targeting E-gene

*F3-E-2 GTACTCATTCTGGAAAG
B3-E-1 AGGAACCTAGAAGAACATGAGT
FIP-E-2 GGATGGCTAGTGAACTAGCAAGGGTACGTTAATAGTTAATAGCGT
BIP-E-2 CGCTTCGATTGTGCGTACGAGAGTAAACGTAAGAAGGTT
LF-E-2 ACCACGAAAGCAAGAAAAAG
LB-E-1 GCTGCAATATTGTTAACGTGAGTCT*

Primer set targeting N gene

N-gene-1

*Gene N-B-F3 * ACCGAAGAGCTACCAGACG
Gene N-B-B3 * TGCAGCATTGTTAGCAGGAT
Gene N-B-FIP * TCTGGCCCAGTCCCTAGGTAGTTCGTGGTGGTACGGTAA
Gene N-B-BIP* AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT
Gene N-B-LF * CCATCTGGACTGAGATCTTCATT
Gene N-B-LB * ACTGAGGGAGCCTGAATACA*

N-gene-2

*F3-N3-1 CCGAAGAGCTACCAGACGAA
B3-N3-1 TGTAGCACGATTGCAGCATT
FIP-N3-1 TCTGGCCCAGTCCCTAGGTAGTGGTGGTACGGTAAAATGAAAG
BIP-N3-1 AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT
LF-N3-1 AGAAATACCATCTGGACTGAG
LB-N3-1 ACTGAGGGAGCCTGAATACAC
RT-LAMP primers (N gene)
Primer Name Sequence Final conc. [nM]
GeneN-A-F3 TGG CTA CTA CCG AAG AGC T 200
GeneN-A-B3 TGC AGC ATT GTT AGC AGG AT 200
GeneN-A-LF (Loop Forward) GGA CTG AGA TCT TTC ATT TTA CCG T 400
GeneN-A-LB (Loop Backward) ACT GAG GGA GCC TTG AAT ACA 400
GeneN-A-FIP (Forward Inner Primer) TCT GGC CCA GTT CCT AGG TAG TCC AGA CGA ATT CGT GGT GG 1600
GeneN-A-BIP (Backward Inner Primer) AGA CGG CAT CAT ATG GGT TGC ACG GGT GCC AAT GTG ATC T 1600*

Internal Control

*RNaseP POP7 F3 TTGATGAGCTGGAGCCA 200
RNaseP POP7 B3 CACCCCTCAATGCAGAGTC 200
RNaseP POP7 LF ATGTGGATGGCTGAGTTGTT 400
RNaseP POP7 LB CATGCTGAGTACTGGACCTC 400
RNaseP POP7 FIP GTGTGACCTGAAGACTCGGTTTAGCCACTGACTCGGATC 1600
RNaseP POP7 BIP CCTCCGTGATATGGCTCTCGTTTTCTTACATGGCTCTGGTC 1600*

RT-qPCR primers [nM]

*E_Sarbeco_R2 ATATTGCAGCAGTACGCACACA 400
E_Sarbeco_P1 ACACTAGCCATCCTTACTGCGCTTCG 200
E_Sarbeco_F1 ACAGGTACGTTAATAGTTAATAGCGT 400
Primer FW IC (Upstream/1/Fw) CATGGGAAGCAAGGGAACTAATG 250
Primer RV IC (Downstream/2/Rv) CCCAGCGAGCAATACAGAATT 250*

Ali, 2020

Ben, 2020

Chow, 2020

Primers targeting orf3a and E genes

F3 "CAAATWCACACAATCGACG" 0.18uM

B3 "TTAACAAATTGCAGCAGTACGCAC" 0.18uM

FIP "GAAACGAATGAGTACATAAGTCGTATGATGARCCGACGACGACTACTA" 0.73uM

BIP "AGGTACGTTAATAGTTAATAGCGTAATCGAAGCGCAGTAAGGATGGCTA" 0.73uM

LoopF "CTTGTGCTTACAAGGCACGCTA" 0.36uM

LoopB "TTGCTTYGTGGTATTCTGCTA" 0.36uM

N-A set for N, 1a-A set for ORF1a for LAMP

Used primers designed by Zhang et al.

Primers targeting ORF1a-A gene

ORF1a-A-F3 CTGCACCTCATGGTCATGTT

ORF1a-A-B3 AGCTCGTCGCCTAAGTCAA

ORF1a-A-FIP GAGGGACAAGGACACCAAGTGTATGGTGAGCTGGTAGCAGA

ORF1a-A-BIP CCAGTGGCTTACCGCAAGGTTTAGATCGGCGCCGTAAC

ORF1a-A-LF CCGTACTGAATGCCTCGAGT

ORF1a-A-LB TTCGTAAGAACGGTAATAAAGGAGC

Primers targeting ORF1a-B gene

ORF1a-B-F3 TCATCAAACGTTCGGATGCT

ORF1a-B-B3 TATGGCCACCAGCTCCTT

ORF1a-B-FIP CGACCGTACTGAATGCCTCGAGAACTGCACCTCATGGTCAT

ORF1a-B-BIP AGACACCTGGTGTCCCTGTCCCAGAAGAACCTGCGGTAAGC

ORF1a-B-LF CTGCTACCAGCTCAACCATAAC

ORF1a-B-LB TCATGTGGCGAATACCAAGT

Primers targeting ORF1a-C gene

ORF1a-C-F3 CTGCACCTCATGGTCATGTT

ORF1a-C-B3 GATCAGTGCCAAGCTCGTC

ORF1a-C-FIP GAGGGACAAGGACACCAAGTGTGGTAGCAGAACTCGAAGGC

ORF1a-C-BIP CCAGTGGCTTACCGCAAGGTTTAGATCGGCGCCGTAAC

ORF1a-C-LF ACCACTACGACCGTACTGAAT

ORF1a-C-LB TTCGTAAGAACGGTAATAAAGGAGC

Primers targeting Gene N-A

GeneN-A-F3 TGGCTACTACCGAAGAGCT

GeneN-A-B3 TGCAGCATTGTTAGCAGGAT

GeneN-A-FIP TCTGGCCCAGTTCTAGGTAGTCCAGACGAATTGTGGTGG

GeneN-A-BIP AGACGGCATCATGGGTTGCACGGGTGCCAATGTGATCT

GeneN-A-LF GGACTGAGATCTTCATTTACCGT

GeneN-A-LB ACTGAGGGAGCCTGAAATACA

Primers targeting Gene N-B

GeneN-B-F3 ACCGAAGAGCTACCGACG

GeneN-B-B3 TGCAGCATTGTTAGCAGGAT

GeneN-B-FIP TCTGGCCCAGTTCTAGGTAGTTCGTGGTGGTAGCGTAA

GeneN-B-BIP AGACGGCATCATGGGTTGCACGGGTGCCAATGTGATCT

GeneN-B-LF CCATCTGGACTGAGATCTTCATT

GeneN-B-LB ACTGAGGGAGCCTTGAATACA

N1, N2 probe/primers sets

- Chelex-100 (Bio-Rad # 1421253)
- WarmStart® Colorimetric LAMP 2 X Master Mix (NEB #M1800S/#M1800L)
- Nuclease free water (VWR # 10220-398)

N2 primers:

N2-F3 "ACCAGGAACATAATCAGACAAG"
N2-B3 "GACTTGATCTTGAAATTGGATCT"
N2-FIP "TTCCGAAGAACGCTGAAGCGGAAC TGATTACAAACATTGGCC"
N2-BIP CGCATGGCATGGAAGTCACAATTGATGGCACCTGTGTA" N2-
LF "GGGGGCAAATTGTGCAATTG"
N2-LB "CTTCGGGAACGTGGTTGACC"

Flynn, 2020

N1 primers:

N1-F3 "TGGACCCAAAATCAGCG"
N1-B3 "GCCTTGTCTCGAGGGAAAT"
N1-FIP "CCACTGCCCTCTCCATTCTGGTAAATGCACCCGCATTACG"
N1-BIP "CGCGATAAAACAACGTCGGCCCTGCCATGTTGAGTGAGA"
N1-LF "TGAATCTGAGGGTCCACCAAA"
N1-LB "GGTTTACCAATAATACTGCGTCTT"

Fowler, 2020

ORFlab probe/primers sets for LAMP
E probe/primers sets for qPCR
Primer sequences not provided

Haq, 2020

Primers targeting ORFlab, N, and S genes
Primer sequences not provided

S probe/primers sets for LAMP
S gene primer
F3 "CTAGGTTCAAA CTTTACTTGC"
F2 "TACATAGA AGTTATTGAG CTCCTGGTGA"
LF "TGATTCTTCTCA GGTTGGACAG C"
F1c "TGGTGCCTGC AGCTTATTAT"
B1c "ATGAAAATGG AACCAATTACA GATGC"
LB "AG ACTGTGCACCTGACCCTC"
B2 "C TCAGAAACAA AGTGTACGTT G"
B3 "AATCCTTC ACTGTAGAAA AAGG"

Hu, 2020

ORFlab, N probe/primers sets for qPCR
Primers targeting N gene
Probe- FAM-TTGCCCCAGCGCTTCA-BHQ1
Forward- TTGGGGACCGAGAACATAAT
Reverse- GAAGGTGTGACTTCCATGC
Primers targeting ORFlab gene

Huang, 2020

Probe- *HEX-TCCCACCAAGAACATAGCATAGATGC-BHQ1*
Forward- *TTTAGATATATGAATTACAGGGAA*
Reverse- *ACCAACACCCAACAATTAAT*
Primers targeting RNP gene
Probe- *Cy5-TCCACAAAGTCCGCGCAGAG-BHQ2*
Forward- *AGATTTGGACCTGCGAG*
Reverse- *ACTGAATAGCCAAGGTGAG*
LAMP primers O117, S17,N1 and N15, which target RNA encoding Orf1ab, S, N for LAMP
Primers targeting N15 gene
F3 AGATCACATTGGCACCCG
B3 CCATTGCCAGCCATTCTAGC
FIP TGCTCCCTCTGCGTAGAACCCAATGCTGCAATCGTGCTAC
BIP GGCGGCAGTCAGCCTCTCCCTACTGCTGCCTGGAGTT
LF GCAATGTTGTTCTTGAGGAAGTT
LB GTTCCTCATCACGTAGTCGCAACA
Primers targeting S17 gene
F3 TCTTCACACGTGGTGTT
B3 GTACCAAAAATCCAGCCTC
FIP CATGGAACCAAGTAACATTGAAAACCTGACAAAGTTTCAGATCC
BIP CTCTGGGACCAATGGTACTAAGAGGGACTTCTCAGTGGAAAGCA
LF GAAAGGTAAGAACAAAGTCCTGAGT
LB CTGTCCTACCATTAAATGATGGTGT
Primers targeting O117
F3 CCCCAAAATGCTGTTGTT
B3 TAGCACGTGGAACCCAAT
FIP GGTTTCAAGCCAGATTCAATTGGATGTCACAATTCAAAGTAGGA
BIP TCTTCGTAAGGGTGGTCGCAGCACACTGTTATGGCAAC
LF TCGGCAAGACTATGCTCAGG
LB TTGCCCTTGGAGGGCTGTGT

Jiang, 2020

ORF1ab, N, E probe/primers sets for qPCR
Primer sequences not provided
Primer set for N gene for LAMP
nCoV-N-F3 CCAGAACATGGAGAACCGCAGTG
nCoV-N-B3 CCGTCACCACCAACGAATT
nCoV-N-FIP AGCGGTGAACCAAGACGCAGGG
CGCGATCAAAACAACG
nCoV-N-BIP AATTCCCTCGAGGACAAGGCGA
GCTCTTCGGTAGTACCCAA
nCoV-N-LF TTATTGGGTAAACCTTGGGGC
nCoV-N-LB TTCCAATTAAACACCAATAGCAGTCC
N gene primer for qPCR
forward "AAA TTT TGG GGA CCA GGA AC"
reverse "TGG CAG CTG TGT AGG TCA AC" 3.2 μM
probe "FAM-ATG TCG CGC ATT GGC ATG GA-TAMRA" 0.4 μM
Unspecified target gene for LAMP

Kitagawa, 2020

Lalli, 2020

LAMP primers targeting ORF1ab and N genes
Primer sequences can be found in the supplementary document of the study

Primers targeting ORR1ab

F3 “TCCAGATGAGGATGAAGAAGA”

B3 “AGTCTGAACAACTGGTGTAAAG”

FIP(F1c+F2) “AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAG”

BIP(B1c+B2) “TCAACCTGAAGAAGAGCAAGAACTGATTGTCCTCACTGCC”

LoopF “CTCATATTGAGTTGATGGCTCA”

LoopB “ACAAACTGTTGGTCAACAAGAC”

Lamb, 2020

ORF1abN1, N2 probe/primer sets for qPCR

Lee, 2020

Primers targeting N1 genes

Primer sequences not provided

Primers targeting N gene

F3 GCCAAAGGCCTCTACGCA

B3 TTGCTCTCAAGCTGGTCAA

FIP TCCCCCTACTGCTGCCTGGAGCAGTCAGCCTCTCGTT

BIP TCTCTGCTAGAACATGGCTGGCATCTGTCAAGCAGCAGCAAAG

LB TGGCGGTGATGCTGCTCTT

S and RdRP LAMP primer sets

S gene primer set (S2)

S2-F3 “ATTCTAACGACACGCCCTAT”

S2-B3 “GAAGATAACCCACATAATAAGCT”

S2-FIP “ACCTATTGGCAAATCTACCAATGGTTAGTCGCGTGATCTCCCT”

S2-BIP “ATCACTAGGTTCAAACCTTACTTGCGCTGTCAACCTGAAGAAGA”

S2-LPF “TTCTAAAGCCGAAAAACCTG”

S2-LPB “CATAGAACGTTATTGACTCCTGGT”

Mohon, 2020

RdRp gene primer set (S3)

S3-F3 “CACCTTATGGGTTGGGATT”

S3-B3 “AACATATAGTGAACCGCCA”

S3-FIP “GTTTGCAGCAAGAACAGTGAATGTGATAGAGCCATGCC”

S3-BIP “ATACAACGTGTTGTAGCTGTACACATGACCATTCACTCAA”

S3-LPF “GGCCATAATTCTAACGATGTTA”

S3-LPB “ATTAGCTAATGAGTGTGCTCAAGTA”

E and N probe/primer sets for qPCR

Primers targeting N gene

F3: AACACAAGCTTCGGCAG,

B3: GAAATTGGATCTTGTCACTCC

FIP: TGCGGCCAATGTTGTAATCAGCCAAGGAAATTGGGGAC,

BIP: CGCATTGGCATGGAAGTCACTTGATGGCACCTGTGTAG,

LF: TTCCTTGTCTGATTAGTTC,

Papadakis, 2020

LB: ACCTTCGGAACGTGGTT

Rödel, 2020

*Primers targeting a 282-bp sequence of the membrane protein (M) gene for LAMP
LightMix® Modular SARS-CoV E-gene primers for qPCR*

Primer sequences not provided

Primers targeting RdRp gene for LAMP

F3 "CCGCCACTAGAGGAGCTACT"

F2 "ATTGGAACAAGCAAATTCTA"

LF "GGTGGTTGGCACACATGTAAAAAC"

FI "TTATAGTGTAGAAAACCTCACC"

B1 "TATGGGTTGGATTATCCTAAATGTG"

LB "AGCCATGCCTAACATGCTTAG"

B2 "CCTCACTTGTCTGCTC"

B3 "TGTGTAGCTTCACAC"

Primers targeting RdRp gene for qPCR

Forward "GTGAAATGGTCATGTGTGGCGG"

Reverse "TATGCTAATAGTGTGTTAACATTG"

Probe "CAGGTGGAACCTCATCAGGAGATGC"

Rohaim, 2020

LAMP primers targeting ORF1a, ORF3a-A, ORF3a-B, ORF7a, N, and M genes

Primer sequences can be found in the supplementary document of the study

Primer sets orf1ab-4 and S-123 for qPCR

orf1ab-F: 5'-CAGACCTCGTCTATGCTTAAGGC-3';

orf1ab-R: 5'-CCCTGGTCAAGGTTAATATAGGCA-3';

Sef: 5'-CTTCCCTCAGTCAGCACCTC-3';

S-R: 5'-AACCAAGTGTGCCATTGA-3'

Yan, 2020

Orf1ab and S gene primers for LAMP not found in text

primer sets targeting the SARS-CoV-2 genome (AS1E targets ORF1ab, ORF1e, and N2)

primers "AS1E" targeting ORF1ab gene

F3 CGGTGGACAAATTGTCAC

B3 CTTCTCTGGATTTAACACACTT

Loop F TTACAAGCTTAAAGAATGTCGAACACT

Loop B TTGAATTAGGTGAAACATTGTCACG

FIP TCAGCACACAAAGCCAAAATTATTTCTGTGCAAAGGAAATTAGGAG

BIP TATTGGTGGAGCTAAACTTAAAGCCTTTCTGTACAATCCCTTGAGTG

primers targeting N2 gene

F3 CGGCAGTCAGCCTCTTC

B3 TTGCTCTCAAGCTGGTCAA

Loop F This set does not require a Loop F primer

Loop B ATGGCGGTGATGCTGCTCTT

FIP TCCCCCTACTGCTGCCCTGGAGCGCTTCCATCACGTAGTCG

BIP TCTCCTGCTAGAATGGCTGGCATCTGTCAAGCAGCAGCAAAG

primers targeting ORF1e

F3 GGCTAACTAACATCTTGGC

B3 GTCAGCACACAAAGCCAA

Loop F TCTTCAAGCCAATCAAGGGAC

Yang, 2020

Loop B TTGTCGGTGGACAAATTGT
FIP TCTCTAACGAAACTCTACACCCCTTTACTGTTATGAAAAACTCAAACC
BIP TATCTAACCTGTGCTTGTGAAATTTAGAATGTCTGAACACTCTCCT

Supplementary Table 6. Summary of index tests and reference tests of all included studies


| Author | Index tests (test of interest) | Reference tests |
|-----------------|--------------------------------|---------------------|
| Ali, 2020a | LAMP(RNA) | qPCR(Superscript) |
| Ali, 2020b | LAMP(RNA) | qPCR(Superscript) |
| Lalli, 2020b | LAMP(direct) | qPCR(ThermoFisher) |
| Kitagawa, 2020 | LAMP(RNA) | Unspecified |
| Lu, 2020 | LAMP(RNA) | qPCR(Liferiver) |
| Lamb, 2020a | LAMP(RNA) | CDC or Luminex |
| Lamb, 2020b | LAMP(RNA) | CDC or Luminex |
| Flynn, 2020a | LAMP(Chelex-100) | qPCR(Seegene) |
| Flynn, 2020b | LAMP(Chelex-100) | qPCR(Seegene) |
| Lee, 2020 | LAMP(one.step) | qPCR(Qiagen) |
| Papadakis, 2020 | qcLAMP | qPCR(NucliSens) |
| Rodel, 2020a | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020b | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020c | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020d | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020e | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020f | LAMP(multiplex) | qPCR(Seegene) |
| Jiang, 2020a | LAMP(RNA) | qPCR(NMPA/DAAN) |
| Jiang, 2020b | LAMP(RNA) | qPCR(NMPA/DAAN) |
| Rodel, 2020g | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020h | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020i | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020j | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020k | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020l | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020m | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020n | LAMP(multiplex) | qPCR(Seegene) |
| Rodel, 2020o | LAMP(multiplex) | qPCR(Seegene) |
| Yan, 2020a | LAMP(RNA) | qPCR(BGI) |
| Yan, 2020b | LAMP(RNA) | qPCR(BGI) |
| Schermer, 2020a | LAMP(multiplex,direct) | qPCR(RealStar) |
| Schermer, 2020b | LAMP(multiplex,direct) | qPCR(RealStar) |
| Mohon, 2020 | LAMP(RNA) | qPCR(BioRad) |
| Ben, 2020 | LAMP(direct) | qPCR(Seegene) |
| Chow, 2020a | LAMP(RNA) | CDC 2019-nCoV pcr |
| Chow, 2020b | LAMP(RNA) | CDC 2019-nCoV pcr |
| Chow, 2020c | LAMP(RNA) | CDC 2019-nCoV pcr |
| Dao, 2020 | LAMP(RNA) | std. PCR |
| Fowler, 2020a | LAMP(direct) | qPCR(Primerdesign) |
| Fowler, 2020b | LAMP(RNA) | qPCR(Primerdesign) |
| Fowler, 2020c | LAMP(saliva) | LAMP(direct) |
| Haq, 2020 | LAMP(RNA) | Unspecified |
| Hu, 2020c | LAMP(RNA) | Diagnostic criteria |
| Hu. 2020d | LAMP(RNA) | Diagnostic criteria |

| | | |
|-------------------|-------------------------------|--------------------|
| Huang, 2020a | LAMP(RNA) | qPCR(Shanghai) |
| Huang, 2020b | LAMP(RNA) | qPCR(Shanghai) |
| Yang, 2020a | LAMP(twostep) | qPCR(ThermoFisher) |
| Yang, 2020b | LAMP(twostep) | qPCR(ThermoFisher) |
| Abasiyanik 2020a | ddPCR(One-step) | Xpert |
| Abasiyanik 2020b | ddPCR(One-step) | Xpert |
| Abasiyanik 2020c | ddPCR(One-step) | Xpert |
| Abasiyanik 2020d | ddPCR(One-step) | Xpert |
| Cassinari, 2020 a | ddPCR(multiplex) | qPCR(Abbott) |
| Cassinari , 2020b | ddPCR(multiplex) | qPCR(Abbott) |
| Dang. 2020b | ddPCR | ABI-7500 |
| Dang. 2020c | ddPCR | ABI-7500 |
| Dong, 2020a | ddPCR | CDC pcr kits |
| Dong, 2020b | ddPCR | CDC pcr kits |
| Dong, 2020c | ddPCR | CDC pcr kits |
| Suo, 2020 | ddPCR(low.viral) | qPCR(BioRad) |
| Yu. 2020a | ddPCR | qPCR(Shanghai) |
| Yu. 2020b | ddPCR | qPCR(Shanghai) |
| Yu, 2020c | ddPCR | qPCR(Shanghai) |
| Abasiyanik 2020e | standard PCR | Xpert |
| Abasiyanik 2020f | standard PCR | Xpert |
| Abasiyanik 2020g | standard PCR | Xpert |
| Abasiyanik 2020h | standard PCR | Xpert |
| Anderson, 2020 | qPCR(multiplex) | CDC 2019-nCoV pcr |
| Freire, 2020 | qPCR(nCoV-QS) | CDC 2019-nCoV pcr |
| Garcia, 2020 | qPCR(triplex) | CDC 2019-nCoV pcr |
| Hasan, 2020 | qPCR(direct) | qPCR(TaqPath) |
| Kandel, 2020 | qPCR(saliva) | qPCR(BioRad) |
| Klein, 2020 | qPCR(magnetic) | qPCR(Qiagen) |
| Konrad, 2020 | qPCR(kits) | qPCR(RealStar) |
| Lalli, 2020a | qPCR(CDC) | qPCR(ThermoFisher) |
| Lubke, 2020 | qPCR(direct) | qPCR(Roche) |
| Moreno, 2020a | qPCR(saliva) | qPCR(StarQ) |
| Moreno, 2020b | qPCR(saliva) | qPCR(StarQ) |
| Pujadas, 2020 | qPCR(Cobas) | CDC 2019-nCoV pcr |
| Ranoa, 2020 | qPCR(saliva/direct/multiplex) | qPCR(TaqPath) |
| Ratcliff, 2020 | qPCR(nested) | qPCR(Altona) |
| Sun, 2020a | qPCR(saliva) | qPCR(Abbott) |
| Sun. 2020b | qPCR(saliva) | qPCR(Abbott) |
| Vaz, 2020 | qPCR(saliva) | qPCR(Parana) |
| Vogels, 2020 | qPCR(saliva/direct) | CDC 2019-nCoV pcr |
| Wang, 2020 | qPCR(nested) | qPCR(Sansure) |
| Wozniak, 2020 | qPCR(aicd pH) | CDC 2019-nCoV pcr |
| Zhen, 2020 | qPCR(multiplex) | CDC 2019-nCoV pcr |

Supplementary Figure 1. Forest plots for LAMP, dPCR, and qPCR


Summary of the subgroup analyses for (a) LAMP, (b) dPCR, and (c) qPCR based on the number of True Positive (TP), False Positive (FP), False Negative (FN), and True Negative (TN) cases in forest plots. The lowercase letters indicate the sub-studies split from the original articles. dPCR had the most consistent diagnostic sensitivity, but least consistent in specificity because dPCR was able to detect qPCR-negative cases. qPCR had both high sensitivity and specificity. LAMP had the least sensitivity, but its specificity was the most consistent among the three tests.

(a)




(b)

dPCR Forest plot




dPCR Forest plot




(c)

qPCR Forest plot




qPCR Forest plot



Supplementary Figure 2. Galaxy plots of dPCR, qPCR, and LAMP studies to visualize heterogeneity.

Each ellipse represents one study, and the red asterisk represents the summary point of all studies in one galaxy plot. Ellipses close to the red asterisk are less heterogeneous. The upper row are galaxy plots for the nucleic-acid test studies with RNA extraction and without RNA extraction. The lower row are plots for tests using different human specimens. dPCR studies were more heterogeneous than qPCR and LAMP studies overall. However, dPCR studies using saliva and sputum specimens are relatively less heterogeneous compared to those using pharyngeal swabs. Most RNA qPCR studies overlapped each other with most significant studies (larger ellipses) small studies lying close to the red asterisk, hence, resulting in small heterogeneity. Heterogeneity of qPCR studies using pharyngeal swabs (red) and saliva (green) was similar, with a few small size studies lying farther from the summary point. LAMP studies with and without RNA extraction were less sparse and were close to the summary point, implying low between-study heterogeneity. Similarly, LAMP studies using saliva and sputum were less heterogeneous.



Supplementary Figure 3. Graph of methodological quality for the 66 studies. Applicability concerns scored higher ratings than the four risk of bias parameters due to various study designs of the studies with over 50% of the studies scored a rating of low concern in patient selection, index test, and reference standard. The overall methodological quality was fair, but the applicability concerns were deemed acceptable.

